 |
Collaboration
Oncothyreon and Merck KGaA of Darmstadt, Germany are collaborating on the development of Stimuvax®. Merck KGaA is responsible for the worldwide clinical development and marketing of Stimuvax. Oncothyreon is eligible for cash payments based on the achievement of certain process transfer events, for BLA submission for first and second cancer indications, for regulatory approval for first and second cancer indications, and for sales milestones. Oncothyreon will receive a royalty based on net sales. Oncothyreon retains responsibility for the manufacture of Stimuvax, including process development and scale-up for commercial manufacturing.
|
|
